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Objectives: Zeel T (Ze14) is a multicomponent medicinal product. Initial preclinical data
suggested a preventive effect on cartilage degradation. Clinical observational studies
demonstrated that Ze14 reduced symptoms of osteoarthritis (OA), including stiffness and
pain. This study aimed to explore these effects further to better understand the mode of
action of Ze14 on human OA chondrocytes in vitro.
Methods: Primary chondrocytes were obtained from the knees of 19 OA patients and
cultured either as monolayers or in alginate beads. The cultures were treated with 20% or
10% (v/v) Ze14 or placebo. For RNA-seq, reads were generated with Illumina
NextSeq5000 sequencer and aligned to the human reference genome (UCSC hg19).
Differential expression analysis between Ze14 and placebo was performed in R using the
DESeq2 package. Protein quantification by ELISA was performed on selected genes from
the culture medium and/or the cellular fractions of primary human OA chondrocyte
cultures.
Results: In monolayer cultures, Ze14 20% (v/v) significantly modified the expression of 13
genes in OA chondrocytes by at least 10% with an adjusted p-value < 0.05: EGR1, FOS,
NR4A1, DUSP1, ZFP36, ZFP36L1, NFKBIZ, and CCN1 were upregulated and ATF7IP,
TXNIP, DEPP1, CLEC3A, and MMP13 were downregulated after 24 h Ze14 treatment.
Ze14 significantly increased (mean 2.3-fold after 24 h, p  0.0444 and 72 h, p  0.0239) the
CCN1 protein production in human OA chondrocytes. After 72 h, Ze14 significantly
increased type II collagen pro-peptide production by mean 27% (p  0.0147). For
both time points CCN1 production by OA chondrocytes was correlated with aggrecan
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(r  0.66, p  0.0004) and type II collagen pro-peptide (r  0.64, p  0.0008) production. In
alginate beads cultures, pro-MMP-13 was decreased by Ze14 from day 7–14 (from −16 to
−25%, p < 0.05) and from day 17–21 (−22%, p  0.0331) in comparison to controls.
Conclusion: Ze14 significantly modified the expression of DUSP1, DEPP1, ZFP36/
ZFP36L1, and CLEC3A, which may reduce MMP13 expression and activation. Protein
analysis confirmed that Ze14 significantly reduced the production of pro-MMP-13. As
MMP-13 is involved in type II collagen degradation, Ze14 may limit cartilage degradation.
Ze14 also promoted extracellular matrix formation arguably through CCN1 production, a
growth factor well correlated with type II collagen and aggrecan production.
Keywords: osteoarthritis, cartilage, chondrogenesis, zeel T, MMP13, multitarget
INTRODUCTION
Osteoarthritis is the most common form of arthritis, affecting
millions of people worldwide. It is a serious disorder primarily
affecting weight bearing joints characterized by cell stress and
extracellular matrix degradation initiated by micro- and macro-
injury that activates maladaptive repair responses, including
proinflammatory pathways of innate immunity. The disease
manifests first as a molecular dysregulation (abnormal joint
tissue metabolism) progressing to anatomical derangements
(characterized by cartilage degradation, bone remodeling,
osteophyte formation, joint inflammation, and loss of normal
joint function) (Kraus et al., 2015). It primarily affects the elderly
population. Due to an increasing number of OA patients, finding
a disease-modifying OA drug, defined as “a drug that inhibits
structural disease progression and also improves symptoms and/
or function” (Barr and Conaghan, 2013), remains an urgent
unmet need. Currently, despite the guidelines, first-line
treatment of OA in daily medical practice remains with
analgesics and anti-inflammatory drugs, although it is
recognized that the long-term use of these drugs is linked to
severe adverse effects (Bannuru et al., 2019). The
recommendations published by medical and scientific societies
are indeed unanimous: their use must be limited. Therefore, it is
essential to find alternative treatments to manage the symptoms
of patients with OA as well as to inhibit structural disease
progression (Geenen et al., 2018; Rausch Osthoff et al., 2018;
Bannuru et al., 2019). Due to the complexity of the disease,
multitarget treatments seem to be more suitable to target the
multiple pathological pathways associated with OA. Zeel T (Ze14)
is a multicomponent medicinal product composed of plant and
organ extracts. Clinical observational studies demonstrated that
Ze14 reduced symptoms of OA, including stiffness and pain, and
was generally well-tolerated with a good safety profile (Gottwald
and Weiser, 2000; Lesiak et al., 2001). Initial preclinical data
suggested a preventive effect of Ze14 on cartilage degradation
(Stancikova, 1999); however, Ze14’s mode of action is still poorly
understood. Due to its promising multitarget nature and the
lack of effective treatment options for OA patients, investigating
the mode of action of Ze14 in OA pathophysiology may
provide important insights explaining at least some effects
observed in the clinical studies with OA patients.
Recently, transcriptome analysis was used to investigate the
effects of natural or chemically produced molecules on
chondrocyte transcriptome in vitro (Gouze et al., 2006; James
et al., 2007; Comblain et al., 2016; Aury-Landas et al., 2017).
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Technologies like Next Generation Sequencing RNA-seq
generate an unbiased view of the transcriptome offering a
wider dynamic range, high sensitivity, and accurate results on
all genes expressed by cells (Wang et al., 2014; Liu et al., 2015; Li
et al., 2016).
This exploratory study aimed to investigate the mode of action
of Ze14 in OA by comparing the transcriptomic profile of human
OA chondrocytes treated with Ze14 or saline as control. The
transcriptomic profile of OA chondrocytes was determined from
primary cell cultures treated with Ze14 at two concentrations,
with or without the addition of IL-1β to activate inflammatory
pathways. Human primary cells retain the morphological and
functional characteristics of their tissue of origin. Thus, we chose
this primary OA cell model to reflect the pathological processes of
knee OA, also considering patient to patient variations. Affected
genes of the most relevant disease pathways were then confirmed
by protein analysis in additional chondrocyte cultures.
MATERIAL AND METHODS
Ethical Statement
Articular cartilage samples from 19 patients with knee OA were
obtained at the time of total knee joint replacement (TKR)
surgery. All participants have signed the informed patient
consent, and the protocol was approved by the ethical
committee of the Catholic University of Louvain
(B403201214793 amendment n°2). All procedures followed the
ethical standards of the responsible committee on human
experimentation (institutional and national) and with the
Helsinki Declaration of 1975, revised in 2000. The
Supplementary File S1 gives an overview of the patients’
characteristics.
Study Medication
Zeel T (Ze14) injection solution was manufactured and bottled in
2.0 mL glass ampoules by Heel GmbH, Germany, according to
GMP standards. The study medication was packaged, shipped,
and labeled by Heel GmbH, Germany. The full composition of
Ze14 injection solution is provided in the Supplementary File 2.
Each 1.1 mL ampoule of the saline control contained 0.9%
sodium chloride for injection.
Study Design
The cartilage samples from the patients were divided into two
groups, one for sequencing and transcriptome generation, and
another for protein quantification by ELISA. The harvested tissue
was enzymatically digested and seeded in monolayer cultures or
suspended in alginate beads depending on the analysis.
Supplementary File 3 gives a detailed overview of the study
design and explains the distribution of tissue samples for the
primary cultures, number of treatment conditions including
controls, time points of sample collection for analyses, and
performed analyses. In short, for transcriptome analysis,
chondrocytes were treated with Ze14 or saline control with or
without the presence of IL-1β to induce the inflammatory state.
Two concentrations of Ze14, 10% (v/v) and 20% (v/v) were used.
For protein analysis, chondrocytes were seeded as monolayers or
suspended in alginate beads to investigate chondrocyte
hypertrophy. Both cultures were treated with either 20% (v/v)
Ze14 or saline control in medium.
Sample Collection
Full-depth articular cartilage was excised and immersed in
Dulbecco’s Modified Eagle Medium (DMEM) (with phenol
red and 4.5 g/L glucose) supplemented with N-(2-
hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid) (HEPES)
(10 mM), penicillin (100 U/mL) and streptomycin (0.1 mg/mL)
(all from Lonza, Belgium). After three washes, chondrocytes were
released from cartilage by sequential enzymatic digestions with
0.5 mg/mL hyaluronidase type IV S (Sigma-Aldrich, Belgium) for
30 min at 37°C, 1 mg/mL pronase E (Merck, Belgium) for 1 h at
37°C and 0.5 mg/mL clostridial collagenase IA (Sigma-Aldrich,
Belgium) for 16–20 h at 37°C. The enzymatically isolated cells
were then filtered through a nylon mesh (70 µm), washed three
times and counted.
Chondrocyte Monolayer Culture
Chondrocytes were dispersed in a suspension of 0.1 x 106 cells/mL
in DMEM supplemented with 10% fetal bovine serum (Biowest,
France), 10 mM HEPES, 100 U/mL penicillin, 0.1 mg/mL
streptomycin, 2 mM glutamine (Lonza, Belgium), 20 μg/mL
proline and 50 μg/mL ascorbic acid (Sigma-Aldrich, Belgium)
and seeded in 6-well plates at the density of 0.2 x 106 cells/well.
Chondrocytes were cultured in monolayer for 5–7 days until 95%
confluence. Only primary cultures were used to ensure the
stability of the chondrocyte phenotype. Chondrocytes were
then cultured 24 h in DMEM supplemented with 1% fetal
bovine serum, 10 mM HEPES, 100 U/mL penicillin, 0.1 mg/mL
streptomycin, 2 mM glutamine, 20 μg/mL proline and 50 μg/mL
ascorbic acid. Afterward, the culture medium was replaced by
fresh culture medium containing either 20% (v/v) saline (control),
20% (v/v) Ze14 or 10% (v/v) Ze14 (lower concentration was
achieved as follows: 8 parts medium: 1 part saline: 1 part Ze14;
corresponding to half of the Ze14 concentration, used only for the
transcriptomic study), with or without the addition of human IL-
1β 10–11 M (Roche, Belgium) (Comblain et al., 2016). Cells were
incubated for 24 h (transcriptome analysis only) or 72 h
(transcriptome and protein analysis). Each culture condition
was carried out in triplicates.
For transcriptome analysis, cells were scrapped after 24 h of
incubation, three wells were pooled, and ribonucleic acid (RNA)
extraction was performed using an RNeasy mini kit according to
the instructions of the manufacturer (Qiagen, Netherlands). Cell
lysates were stored frozen at −80°C until RNA extraction.
For LDH release assay, conditioned culture media was
collected after 24 h of incubation and assayed immediately.
Cells were scraped and homogenized in 500 µL of Tris-HCl
buffer by ultrasonic dissociation for 20 s at 4°C, to measure
total LDH content. Remaining conditioned culture media was
stored at −20°C until further analysis.
For protein analyses, conditioned culture media was collected
after 24 h and 72 h of incubation and was then stored at −20°C
until further analysis. Three wells were used per condition. Cells
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were trypsinized and homogenized in 500 µL of Tris-HCl buffer
by ultrasonic dissociation for 20 s at 4°C to measure total DNA
content after 24 h and 72 h of incubation.
Chondrocyte Alginate Beads Culture
Chondrocytes were suspended in alginate beads (as described
(Sanchez et al., 2002)) and cultured for 28 days in Dulbecco’s
modified Eagle’s medium supplemented with 10% FBS, 10 mM
HEPES, penicillin (100 U/mL) and streptomycin (100 μg/mL),
200 μg/mL glutamine, 50 μg/mL ascorbic acid, and 2 mM proline
to induce hypertrophy (Pesesse et al., 2013). Alginate beads
containing chondrocytes were placed in 24-well plates, nine
beads per well. Six wells were used per time point and
treatment: three wells per condition were used for the analyses
of the alkaline phosphatase activity and the protein pro-MMP-13
production, and three other wells for RNA extraction and type X
collagen gene expression.
Ze14 or saline control was added at 20% (v/v) in the culture
medium with every culture medium replacement (from day 0 to
day 24). The culture medium was changed twice a week.
At each time point (Day 3-7-14-17-21-24-28), cell culture was
stopped, and supernatantwas collected and stored at−20°C for further
analysis. Additionally, supernatant was collected on day 10. The beads
of each well were rinsed in NaCl 0.9% and then dissolved in 1mL of
0.1M citrate for 10min. The resulting suspension was centrifuged at
1200 rpm for 10min.With thismethod, 2 fractionswere collected: the
supernatant containing macromolecules that originated from further-
removed matrix (FRM) and pellet-containing cells with their
associated matrix (CM). These two fractions CM and FRM were
kept separately at−20°C until analysis. The supernatant from the FRM
was not used for the analyses. CM of 3 wells was homogenized in
500 µL of Tris-HCl buffer by ultrasonic dissociation for 20 s at 4°C to
measure total DNA content and alkaline phosphatase activity. The
CM of the remaining 3 wells were homogenized in Lysis buffer for
ribonucleic acid (RNA) extraction using RNeasymini kit according to
the instructions of the manufacturer (Qiagen, Netherlands). Cell
lysates were stored frozen at −80°C until RNA extraction.
LDH Viability Test
Cell viability was estimated by quantifying the release of LDH into
the culture supernatant as previously described (Mathy-Hartert
et al., 2009). In brief, a sample of the supernatant or dilutions of
standard solution (LDH from rabbit muscle, from Roche, Belgium)
was mixed with Tris buffer (10 mM Tris-HCl (pH 8.5), 0.1% bovine
serum albumin) containing 800mM lactate. Then, colorimetric
reagent, 1.6 mg/mL iodonitrotetrazolium chloride (Sigma-Aldrich,
Belgium), 4 mg/mL nicotinamide adenine dinucleotide (Roche
Diagnostics, Belgium), and 0.4 mg/mL phenazine methosulfate
(Sigma-Aldrich, Belgium), was added, and the solution was
discoloured red after 10 min of incubation at room temperature.
The percentage of cell death was obtained by comparing the LDH
release into the supernatant to the total LDH concentration (cell and
supernatant).
DNA Quantification
DNA content of all cell cultures was measured according to a
fluorometric method (Labarca and Paigen, 1980). In brief, 200 µL
of 2 μg/mL Hoechst dye solution (Sigma Aldrich, Belgium)−in a
buffer containing 50mMPO4 and 2MNaCl−was added to 50 µL of
sample. After 30min incubation time in the dark, 356 nm excitation/
458 nm emission was read in a spectrophotometer. Placental DNA
(Sigma Aldrich, Belgium) was used for the standard curve.
RNA Extraction
Total RNA was extracted using an RNeasy mini kit (Qiagen,
Belgium) according to the instructions of the manufacturer.
The yield of the extracted RNA was determined
spectrophotometrically by measuring the optical density at
260 nm. For transcriptome analysis, the purity and quality of
extracted RNA was further evaluated using an RNA Nano 6000
Bioanalyzer Agilent (Santa Clara, United States) according to the
manufacturer’s instructions. High-quality RNAwith RNA quality
indicator scores (RIN) of >8 were used.
RNA-Seq and Differential Gene Expression
Analysis
One µg of RNA from each culture condition was used for this
analysis. Libraries were prepared with the Illumina Truseq
stranded mRNA sample prep kit according to the
manufacturer’s instructions. Based on poly(A) selection of
mRNAs, the coding strand information was kept. Sixty (60)
libraries were generated. Poly(A) plus RNA was enriched
using oligo (dT) beads followed by fragmentation and reverse
transcription. Afterward, the 5′ and 3′ ends of cDNA fragments
were prepared to ensure efficient ligation of “Y” adapters
containing a unique barcode and primer binding sites. Finally,
ligated cDNAs were PCR-amplified to be ready for cluster
generation and sequencing.
Sequencing was performed on Illumina NextSeq5000, Single-
Read 75 bp read length, high output mode 2017–2018 (Maximum
Reads per Run: 400 million clusters), 60 libraries per run, and
using 3 runs per library, generating around 20 M reads per sample
(Chaitankar et al., 2016). Denaturated NGS library fragments
were flowed across a flow cell and hybridized on a lawn of
complementary Illumina adapter oligos. Complementary
fragments were extended, amplified via bridge amplification
PCR and denaturated, resulting in clusters of identical single-
stranded library fragments. Fragments were primed and
sequenced utilizing reversible terminator nucleotides. Base
pairs were identified after laser excitation and fluorescence
detection.
Raw data was demultiplexed into individual libraries. After
filtering out reads mapping to rRNA, tRNA, mitochondrial RNA,
and other contaminants, (e.g. adapters, etc.) using bowtie2, reads
were aligned onto the human reference genome (UCSC hg19
annotation) and quantified with Star to give the Counts file.
Quality control of sequencing reads was assessed with FASTQC
and quality control after mapping with Picard tools. Compilation
of tool metrics was performed with MultiQC.
Differential expression analysis was made in R (version 3.4.3
(2017–11–30), https://www.R-project.org/) using the DESeq2
package (1.18.1) and R code design  ∼ Patient + Treatment.
Analysis was performed with treatment as contrast:
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• Saline control vs Ze14 20% (v/v)
• Saline control vs Ze14 10% (v/v)
• Saline control vs Ze14 20% (v/v), both with IL-1β
• Saline control vs Ze14 10% (v/v), both with IL-1β
Alternatively, the interaction “Patient:Treatment” was added
to the R code design to evaluate if the treatment effect varied from
patient to patient. False Discovery Rate of 0.05 was used to assess
the statistical significance.
Alkaline Phosphatase Activity
The enzymatic activity of alkaline phosphatase normalized to the
DNA content of the respective well was analyzed in the alginate
beads cultures according to the previously described method
(Sanchez et al., 2005). In brief, 50 µL of cell extract were
incubated with 100 µL of p-nitrophenylphosphate (liquid
p-NPP, ready to use, Sigma Aldrich, Belgium). In the presence
of ALP, p-NPP is transformed to p-nitrophenol and inorganic
phosphate. p-nitrophenol absorbance is measured at 405 nm,
after 10 min of incubation at 37°C. A standard preparation of
p-nitrophenol was used for calibration. Results were expressed in
nmoles of p-nitrophenol released per min and per µg of DNA.
Quantitative Real-Time RT-PCR Gene
Expression
Reverse transcription was executed by using sensiscript kit
according to the instructions of the manufacturer (Qiagen,
Belgium), and cDNA was kept at −20°C. Polymerase chain
reaction was performed by using the Rotor Gene (Qiagen,
Belgium)—SYBR premix Ex Taq (Takara, Belgium). The PCR
template source was either first-strand cDNA (10 ng) or purified
DNA standard. The PCR program comprised an initial
denaturation step at 95°C for 10 s followed by 40 cycles of
denaturation at 95°C for 5 s and then an annealing/extension
step at 60°C for 25 s. Followed by an ending melting step from
65°C to 96°C with a 1°C increase each second. The following primer
sequences were used to amplify the desired cDNA: Hypoxanthine-
guanine phosphoribosyltransferase forward 5′-TGTAATGAC
CAGTCAACAGGG-3′ and reverse 5′-TGCCTGACCAAGGAA
AGC-3′ and COL10A1 forward 5′-GGGAGTGCCATCATCG-3′
and reverse 5′-AGGGTGGGGTAGAGTT-3′. HPRT was used as
an internal standard and the ratio of genes toHPRTwas calculated.
After HPRT normalization for COL10A1, relative expression was
calculated.
ELISA for CCN1, Pro-MMP-13, Aggrecan
and Type II Collagen Pro-Peptide
Protein amount of aggrecan was assessed from the supernatant
and the cell pellet while the protein amount of type II collagen
pro-peptide, CCN1, and pro-MMP-13 was only measured from
the supernatant, by specific enzyme amplified sensitivity
immunoassays (Aggrecan: Diasource, Belgium PG EASIA
KAP1461, batch 1902–2260; CCN1: CYR61 R&Dsystems UK
DuoSet DY4055, batch P161032; collagenase 3 precursor -pro-
MMP-13-: R&Dsystems UK DuoSet DY913, batch P196342; type
II collagen pro-peptide: R&Dsystems UK DuoSet DY7589–05,
batch P151876). Aggrecan, type II collagen pro-peptide, and
CCN1 were assayed from chondrocytes in monolayer cultures,
and pro-MMP-13 was analyzed from chondrocytes of alginate
beads hypertrophic cultures. Protein content was normalized to
the DNA content.
Statistical Analysis
For the transcriptome analysis, DESeq2 Bioconductor package
was used for normalization, principal component analysis, and
differential gene expression. DESeq2 differential gene analysis
was based on the hypothesis that most genes were not
differentially expressed (Anders and Huber, 2010; Love et al.,
2014). The method was based on the negative binomial
distribution model. Within the DESeq2 package, and with the
estimateSizeFactorsForMatrix function, scaling factors were
calculated for each run. After dividing gene counts by each
scaling factor, DESeq2 values were calculated as the total of
rescaled gene counts of all runs.
The amplitude of changes is represented either in the log2 Fold
Change format (classical representation from DESeq2, where “0”
means “no change,” “1” means “2-fold induction” and “−1”
means “2-fold decrease”) or in Fold Change (where “1” means
“no change,” “2” means “2-fold induction” and “0.5” means “2-
fold decrease”).
Along with the standard p-value, an adjusted p-value (padj)
was calculated. The adjustment methods included the Bonferroni
correction (“bonferroni”) in which the p-values were multiplied
by the number of comparisons. Less conservative corrections
were also included by Holm (“holm”) (Holm, 1979), Hochberg
(“hochberg”) (Hochberg, 1988), Hommel (“hommel”) (Hommel,
1988), Benjamini and Hochberg (“BH” or its alias “fdr”)
(Benjamini and Hochberg, 1995), and Benjamini and Yekutieli
(“BY”) (Benjamini and Yekutieli, 2001), respectively. The “BH”
(aka “fdr”) and “BY” method of Benjamini, Hochberg, and
Yekutieli control the false discovery rate, the expected
proportion of false discoveries among the rejected hypotheses.
For the protein analyses, results were statistically analyzed
using GraphPad Prism 6.0. Before calculating the statistical
difference, a Kolmogorov-Smirnov normality test and a ROUT
outlier test were performed. For monolayer experiments, either a
ratio paired t-test, or a Wilcoxon matched-pairs signed-rank test
was used. For alginate beads experiments, paired one-way
ANOVA was used to compare Ze14 to saline control at each
time point. Furthermore, for cumulative pro-MMP-13
production, two-way ANOVA was used to evaluate the kinetic
effect of the treatment. For assessing the correlation between two
factors, Pearson’s test was used for normal data distribution, and
Spearman’s test was used non-normal distribution.
RESULTS
Cell Viability and RNA-Seq Database
Analysis
Cell viability was higher than 98% and was not affected by IL-1β
and/or Ze14 treatment, either at 10% or 20% (v/v)
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(Supplementary File 4). RNA-seq experiments were performed
with a sequencing depth of 16.75 ± 0.52 million copies of genes
per sample. IL-1β 10–11M drastically modified the gene
expression pattern of human OA chondrocytes. Principal
component analysis (PCA) with regularized-logarithm
transformation showed that the large variance between the
samples was related to the IL-1β stimulation, explaining 86.9%
of the total variance (PC1) (Supplementary File 5). The database
was then split into basal and IL-1β-treated samples to continue
the analysis.
Ze14Modulated the Expression of 13 Genes
Under Basal Conditions
Under basal conditions, chondrocytes expressed genes
representing a well-differentiated and mature chondrogenic
cell type as confirmed by the top-count genes, with a high
level of type II collagen (COL2A1–third-most counted, 6-times
more than COL1A1) and aggrecan (ACAN–eighth-most
counted) gene expression (Supplementary File 6).
According to the DESeq2 analysis and in basal condition,
Ze14 20% (v/v) significantly modified the expression of 13 genes
by at least ± 10% of Fold Change with a padj <0.05 (Table 1;
Figure 1A, full results in Supplementary File 6). Ze14 10% (v/v)
failed to significantly modify gene expression.
The treatment dose-response of each patient sample is
illustrated in the Supplementary File 7A (upregulated DEGs)
and 7B (downregulated DEGs).
IL-1β Induced the Expression of
Proinflammatory Genes in Human OA
Chondrocytes
IL-1β treatment induced a strong upregulation of
proinflammatory cytokines including chemokines. Top 12
cytokines produced by OA chondrocytes were in descending
order of expression: CXCL8 (∼20.000-fold increase), IL-6,
CXCL1, CCL20, CXCL6, CCL2, CXCL3, CXCL2, CXCL5,
CCL5, IL-11, and CCL8. CXCL12 and CXCL14 were
downregulated by IL-1β. Complete results of differentially
expressed genes (DEGs) with IL-1β treatment are in
Supplementary File 8. In presence of IL-1β 10–11 M, Ze14 20%
(v/v) modified the expression of lipopolysaccharide binding
protein (LBP, +17%, padj  0.0126) and E-selectin (SELE,
−11%, padj  0.0252) (Figure 1B). Furthermore, Ze14 also
increased the expression of CCN1 (+12%, p  0.0026) and
EGR1 (+46%, p  0.0014) and reduced the expression of
two genes encoding key enzymes of the kynurenine pathway
of tryptophan degradation, kynureninase (KYNU, −16%,
p  2.84*10–7) and indoleamine 2,3-dioxygenase 1 (IDO1,
−21% p  5.96*10–5) that had been upregulated by IL-1β (5.78
and 8.81 log2 Fold Change, respectively). Complete results are in
the Supplementary Files 7C and 9.
Ze14 Promoted Extracellular Matrix
Formation Through CCN1 Production
Cellular communication network factor 1 (CCN1), also known as
CYR61, is a growth factor-inducible immediate-early gene, induced
notably by TGF-β, shown to be important in chondrogenesis
(Chijiiwa et al., 2015). The stimulating effect of Ze14 20% (v/v)
on CCN1 production was confirmed by immunoassay. CCN1 was
assayed in the culture supernatant of six monolayer chondrocyte
cultures from six independent OA patients. Ze14 significantly
increased (2.3-fold ± 1.2 after 24 h, p  0.0444 and 2.3-fold ± 1.0
after 72 h, p  0.0239) the CCN1 protein production by human OA
chondrocytes (Figure 2A). Because CCN1 inhibits the activity of
ADAMTS-4, an important enzyme involved in aggrecan
degradation, and has been shown to increase aggrecan and type
II collagen synthesis in chondrocytes (Wong et al., 1997; Chijiiwa
et al., 2015), we also quantified the protein production of both
molecules in these cell cultures. After 72 h, Ze14 20% (v/v) slightly
but not significantly increased aggrecan production (14 ± 19%, p 
0.1117, Figure 2B) and significantly increased type II collagen pro-
peptide production by 27 ± 20% (p  0.0147, Figure 2C). For both
time points, CCN1 production by OA chondrocytes was positively
TABLE 1 | Differentially expressed genes in chondrocytes treated with Ze14 20% (v/v) compared to saline control using the DESeq2 R package designed for RNA-seq
differential gene expression paired-analysis. baseMean is the mean of normalized counts of all samples, normalizing for sequencing depth. padj: False Discovery Rate
(FDR) adjusted p-value (for details see material and method, statistics paragraph).
GeneName baseMean log2 Fold
Change
Fold Change p-value padj
ATF7IP Activating transcription factor 7 interacting protein 1249 −0.1585 0.896 2.01E-05 0.0153
DEPP1 DEPP1, autophagy regulator 1649 −0.1792 0.883 2.71E-05 0.0189
CLEC3A C-type lectin domain family 3 member A 1132 −0.1902 0.877 7.14E-06 0.0108
CCN1 Cellular communication network factor 1 26,310 0.1845 1.136 4.81E-06 0.0087
DUSP1 Dual specificity phosphatase 1 738 0.2363 1.178 8.38E-05 0.0448
EGR1 Early growth response 1 1468 0.9481 1.929 1.93E-05 0.0153
FOS Fos proto-oncogene, AP-1 transcription factor subunit 188 0.9058 1.874 4.44E-05 0.0269
MMP13 Matrix metallopeptidase 13 566 −0.2924 0.817 2.73E-07 0.0008
NFKBIZ NFKB inhibitor zeta 685 0.2116 1.158 1.61E-05 0.0146
NR4A1 Nuclear receptor subfamily 4 group a member 1 201 0.5149 1.429 8.76E-06 0.0111
TXNIP Thioredoxin interacting protein 2047 −0.1696 0.889 2.29E-07 0.0008
ZFP36 ZFP36 ring finger protein 599 0.2327 1.175 4.24E-05 0.0269
ZFP36L1 ZFP36 ring finger protein like 1 4000 0.1950 1.145 1.67E-08 0.0002
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and significantly correlated with aggrecan (r  0.66, p  0.0004,
Figure 2D) and type II collagen pro-peptide (r  0.64, p  0.0008,
Figure 2E) production.
Ze14 Decreased the Production of
Pro-MMP-13 in a Hypertrophy-Independent
Pathway
RNA-seq revealed that Ze14 acts on matrix metallopeptidase 13 as
well as on several independent genes involved in MMP13 regulation
and activation (Figure 3A). MMP-13 is a major enzyme involved in
OA pathology: it is both a marker for hypertrophy in chondrocytes
and is known to function as an extracellular matrix-degrading
enzyme in OA joints (Li et al., 2017). To investigate MMP-13
production during hypertrophic chondrocyte differentiation, we
cultured primary OA chondrocytes for 28 days in the alginate
beads model in the presence of 10% FBS. We have previously
shown that articular chondrocytes become hypertrophic between
21 and 28 days of culture in these conditions (Pesesse et al., 2013;
Pesesse et al., 2014). Fresh Ze14 20% (v/v) was added to the culture
media twice a week during these 28 days.
In the alginate beads model, pro-MMP-13 production highly
increased between day 3 and day 14 and then decreased
independent of the treatment (Figure 4A). Interestingly, pro-
MMP-13 was significantly decreased in Ze14-treated cultures from
day 7–14 (from −16 to −25%, p < 0.05) and from day 17–21 (−22%,
FIGURE 1 |Differentially expressed genes by Ze14 20% (v/v) with Fold Change >1.1 or <0.9, expressed as log2 Fold Change (mean ± SE, n  10). (A): without IL-1β
treatment, (B): with IL-1β 10–11 M treatment.
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p  0.0331) in comparison to saline-treated control cultures. The
cumulative pro-MMP-13 production over 28 days was significantly
lower in Ze14-treated chondrocyte cultures than in saline-treated
control cultures (p < 0.0001, Figure 4B).
To analyze the Ze14 effect on the terminal hypertrophy
differentiation, we investigated AP activity and type X collagen
gene expression. These markers of hypertrophy increased with
culture time, confirming that an induction of hypertrophy took
place in these experimental conditions (data not shown). Ze14
did not modify AP activity or COL10A1 expression
(Supplementary File 10).
DISCUSSION
In this study, we aimed to identify molecular pathways in human
OA chondrocytes treated with Ze14. We used the latest NGS
technology to generate the transcriptome, capturing dynamic
changes in chondrocytes induced by the treatment, compared to
saline control. We extended our transcript-level analysis to the
protein level by directly measuring proteins with ELISA. Here we
demonstrate that Ze14 promotes extracellular matrix formation
arguably through CCN1 production and reduced pro-MMP-13,
which may limit cartilage degradation. These findings may
FIGURE 2 | Effect of Ze14 on CCN1, aggrecan and type II collagen pro-peptide production by OA chondrocytes cultured as monolayer (n  6). Saline-treated cells
served as controls. Results are shown as mean ± SD of the cultures (n  6). Each dot represents individual culture means. Data were statistically analyzed using paired
t-test, correlations were analyzed using Pearson’s for aggrecan and Spearman’s for type II collagen pro-peptide.
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explain some effects observed in the clinical studies with OA
patients.
Most of Ze14 DEGs were involved in MMP-13, also known as
collagenase 3, regulation pathways (Figure 4A), including expression
of MMP13 itself. It is known that MMP13 is significantly
overexpressed in the joints and articular cartilage in patients with
OA, and is a major proteinase involved in the degradation of type II
collagen, a key constituent of the extracellular matrix (Li et al., 2017).
Indeed, Ze14 modified DUSP1, DEPP1, ZFP36, ZFP36L1, and
CLEC3A, which are signaling factors regulating MMP13
expression and activation. Furthermore, long-term (28 days)
treatment with Ze14 significantly reduced the production of pro-
MMP-13, the inactive precursor of MMP-13. The data analysis
suggests that Ze14 potentially limits type II collagen degradation by
reducing MMP-13 production and could have a beneficial effect on
cartilage degradation.
Other notable results of this study are the stimulating effects of
Ze14 on type II collagen and CCN1 production in human OA
chondrocytes showing that Ze14 has proanabolic properties on
cartilage.
During chondrogenic differentiation, chondrocytes express a
mature chondrogenic phenotype (a set of characteristics specific to
mature chondrocytes present in healthy cartilage). In adult
cartilage, it involves the synthesis of matrix components, mainly
type II collagen and aggrecan, two molecules characteristic of
cartilage extracellular matrix, without changing the cell number.
CCN1 is a growth factor-inducible immediate-early gene, directly
involved in chondrogenesis: in micromass culture, purified
recombinant CCN1 protein promoted chondrogenesis
demonstrated by the expression of type II collagen, increased
[35 S] sulfate incorporation, and larger alcian-blue staining of
cartilage nodules used to assess aggrecan. Aggrecan is the major
proteoglycan of the cartilage matrix. (Wong et al., 1997; Chijiiwa
et al., 2015). Furthermore, CCN1 inhibits the activity of
aggrecanase-1, also known as ADAMTS-4, an important
FIGURE 3 | Effects of Ze14 20% (v/v) on pro-MMP-13 production by
chondrocytes in alginate beads culture. Saline-treated cells served as
controls. Results are shown as mean ± SD of the cultures (n  4). Data were
statistically analyzed using paired one-way ANOVA (A) or two-way
ANOVA (B).
FIGURE 4 | (A): Mechanisms of action of Ze14 on MMP-13 production
by chondrocytes: Ze14 significantly modified the expression of DUSP1,
DEPP1, ZFP36, ZFP36L1 and CLEC3A, which are pathway mediators
involved in MMP13 expression and activation, and reduced the
production of pro-MMP-13. This may limit cartilage degradation. Upregulation
and downregulation by Ze14 are indicated in green and red color, respectively.
(B): Mechanisms of action of Ze14 on chondrogenesis: Ze14 has a
proanabolic effect on chondrocytes arguably through CCN1 production. Ze14
increased type II collagen and CCN1 production. Green color indicate
upregulation by Ze14.
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enzyme involved in aggrecan degradation. Arguably, by increasing
CCN1, Ze14 could prevent aggrecan degradation and increase the
synthesis of type II collagen and aggrecan (proanabolic effect).
Interestingly, we found that type II collagen and aggrecan
production were correlated with CCN1 production, suggesting
that CCN1 could be a signaling factor involved in Ze14’s anabolic
effect on chondrocytes. The correlation between aggrecan and
CCN1 has previously also been observed using alcian-blue staining
(Wong et al., 1997).
These results demonstrate that Ze14 increases cartilage matrix
formation in OA chondrocytes, arguably via CCN1, promoting
chondrogenesis (Figure 4B). That is an important finding since
chondrocytes lose their “healthy” chondrogenic properties and
change into hypertrophic, catabolic, or fibroblastic chondrocytes
as OA develops and progresses. However, in our in vitro
hypertrophy model, Ze14 failed to stop or delay the terminal
hypertrophic differentiation of chondrocytes. One reason could
be that activation of hypertrophic differentiation pathways in
chondrocytes obtained from our patients might have already been
too advanced. Using healthy chondrocytes from young donors
could reveal different outcomes. Furthermore, additional studies
are needed to investigate the effect of Ze14 on fibroblastic
chondrocytes.
Interestingly, Ze14 increased the expression of two key signaling
factors involved in chondrogenesis: Early Growth Response (EGR)
1 and FOS. SOX9 is upregulated through the induction of EGR1,
EGR3 and FOS mRNA (Spaapen et al., 2013). SOX9 is the
transcription factor involved in chondrogenesis known to
increase the expression of type II collagen and aggrecan in
chondrocytes (Oh et al., 2010). Arguably, the upregulation of
EGR1 and FOS by Ze14 has a beneficial effect on
chondrogenesis and potentially leads to an increased anabolism.
Finally, we have observed that Ze14 may modulate the harmful
effect of IL-1β on chondrocyte metabolism. IL-1β is considered as
one of themajor proinflammatorymediators inOA. Besides, IL-1β is
a potent stimulatory and deleterious cytokine, and IL-1β stimulation
of chondrocytes is the most widely used in vitromodel in OA. In the
presence of IL-1β 10–11M, Ze14 20% (v/v) increased CCN1, LBP,
and EGR1, and decreased expression of E-selectin and of two
enzymes of the kynurenine pathway of tryptophan degradation,
kynureninase and indoleamine 2,3-dioxygenase 1.
E-selectin is an adhesion molecule mediating the initial rolling
of leukocytes along the surface of the vascular endothelium before
firm adhesion and migration of the leukocytes occurs. It has been
reported that both P- and E-selectin are expressed on the vascular
endothelium of the synovium in rheumatoid arthritis (RA), and
high levels of soluble E-selectin are detectable in the synovial fluid
in RA. E-selectin plays an important role early in the development
of adjuvant-induced arthritis in the rat (Issekutz et al., 2001). In
our study, E-selectin was highly upregulated with IL-1β (12.6 log2
Fold Change) and was reduced by Ze14 treatment. Therefore, we
assume that the initial rolling and the subsequent recruitment of
leukocytes is inhibited in the presence of Ze14, leading to a
reduction of inflammation. To confirm the potential effect on
inflammation, further investigations would be necessary.
Another important effect of Ze14 during IL-1β-treatment was
observed on two enzymes of the kynurenine pathway of
tryptophan degradation, kynureninase and indoleamine 2,3-
dioxygenase 1. These enzymes were highly upregulated with
IL-1β stimulation (5.78 and 8.81 log2 Fold Change,
respectively), and were decreased after Ze14 treatment (−16%
and −21%). Elevated tryptophan metabolism and kynurenine
levels have also been shown in primary synovial cell cultures in
response to elevated interferon-γ, suggesting altered or increased
tryptophan metabolism in response to inflammatory cytokines
associated with arthritis (Malone et al., 1994). In this instance,
further understanding of the impact of disease progression on
tryptophan/kynurenine metabolism could benefit from further
analysis of this pathway in OA.
In conclusion, in primary OA chondrocyte cultures, Ze14
promoted extracellular matrix formation probably through
CCN1 production, a growth factor well-correlated with type II
collagen and aggrecan production. Ze14 also significantly modified
the expression of DUSP1, DEPP1, ZFP36, ZFP36L1, and CLEC3A,
which are pathway mediators involved in MMP13 expression and
activation. Long-term treatment with Ze14 significantly decreased
pro-MMP-13 production, which is the inactive precursor of the
metallopeptidase 13 involved in type II collagen degradation. For
confirmation whether the effect of Ze14 on pro-MMP-13 has
indeed an impact on type II collagen and cartilage matrix
degradation, further investigations would be necessary, such as
the analysis of protein activation (pro-MMP-13 to active MMP-
13), the determination of MMP-13 enzymatic activity, and the
analysis of type II collagen degradation biomarkers in vivo.
Our analyses show that Ze14 is a multitarget medication
reducing several characteristics of OA: it decreased pro-MMP-
13, potentially inhibiting catabolism, and demonstrated anabolic
properties probably driven by CCN1, leading to a global net
increase of chondrogenesis, characterized by a stimulation of type
II collagen synthesis.
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